Michelle L Lamb

List of Publications by Year
in descending order

42 papers	3,203 citations	186265 28 h-index	276875 41 g-index
44 all docs	44 docs citations	44 times ranked	5239 citing authors

#	Article	IF	Citations
1	Accurate Prediction of the Relative Potencies of Members of a Series of Kinase Inhibitors Using Molecular Docking and MM-GBSA Scoring. Journal of Medicinal Chemistry, 2006, 49, 4805-4808.	6.4	575
2	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature Communications, 2018, 9, 5341.	12.8	356
3	AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood, 2014, 123, 905-913.	1.4	205
4	A Computational Ensemble Pharmacophore Model for Identifying Substrates of P-Glycoprotein. Journal of Medicinal Chemistry, 2002, 45, 1737-1740.	6.4	186
5	Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain. Nature Chemical Biology, 2016, 12, 931-936.	8.0	153
6	Computational approaches to molecular recognition. Current Opinion in Chemical Biology, 1997, 1, 449-457.	6.1	124
7	Discovery of 5-Chloro-N²-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N⁴-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4,6-triamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway. Journal of Medicinal Chemistry, 2011, 54, 262-276.	6.4	120
8	Performance of 3D-Database Molecular Docking Studies into Homology Models. Journal of Medicinal Chemistry, 2004, 47, 764-767.	6.4	113
9	Trk kinase inhibitors as new treatments for cancer and pain. Expert Opinion on Therapeutic Patents, 2009, 19, 305-319.	5.0	102
10	Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4599-4604.	2.2	94
11	Prediction of Binding Affinities for TIBO Inhibitors of HIV-1 Reverse Transcriptase Using Monte Carlo Simulations in a Linear Response Method. Journal of Medicinal Chemistry, 1998, 41, 5272-5286.	6.4	87
12	Discovery and Mechanistic Study of a Small Molecule Inhibitor for Motor Protein KIFC1. ACS Chemical Biology, 2013, 8, 2201-2208.	3.4	87
13	Estimation of the binding affinities of FKBP12 inhibitors using a linear response method. Bioorganic and Medicinal Chemistry, 1999, 7, 851-860.	3.0	75
14	Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases. Journal of Medicinal Chemistry, 2008, 51, 4672-4684.	6.4	73
15	Design, docking, and evaluation of multiple libraries against multiple targets. Proteins: Structure, Function and Bioinformatics, 2001, 42, 296-318.	2.6	66
16	Evaluating Free Energies of Binding and Conservation of Crystallographic Waters Using SZMAP. Journal of Chemical Information and Modeling, 2015, 55, 1552-1565.	5.4	64
17	Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies. Journal of Medicinal Chemistry, 2020, 63, 15564-15590.	6.4	57
18	Ensemble-Based Docking Using Biased Molecular Dynamics. Journal of Chemical Information and Modeling, 2014, 54, 2127-2138.	5.4	53

#	Article	IF	Citations
19	Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors. ACS Medicinal Chemistry Letters, 2017, 8, 239-244.	2.8	53
20	Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5743-5747.	2.2	52
21	Pyrimidinone Nicotinamide Mimetics as Selective Tankyrase and Wnt Pathway Inhibitors Suitable for in Vivo Pharmacology. ACS Medicinal Chemistry Letters, 2015, 6, 254-259.	2.8	51
22	Targeting adenosine A_{2A} receptor antagonism for treatment of cancer. Expert Opinion on Drug Discovery, 2018, 13, 997-1003.	5.0	49
23	Deconvoluting Kinase Inhibitor Induced Cardiotoxicity. Toxicological Sciences, 2017, 158, 213-226.	3.1	45
24	Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Medicinal Chemistry Letters, 2012, 3, 705-709.	2.8	39
25	Structureâ€Based Design of Selective Noncovalent CDK12 Inhibitors. ChemMedChem, 2018, 13, 231-235.	3.2	37
26	Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer. Cancer Research, 2018, 78, 6691-6702.	0.9	36
27	Discovery of Potent KIFC1 Inhibitors Using a Method of Integrated High-Throughput Synthesis and Screening. Journal of Medicinal Chemistry, 2014, 57, 9958-9970.	6.4	34
28	Investigations of Neurotrophic Inhibitors of FK506 Binding Protein via Monte Carlo Simulations. Journal of Medicinal Chemistry, 1998, 41, 3928-3939.	6.4	31
29	Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6524-6528.	2.2	25
30	Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles. Journal of Medicinal Chemistry, 2019, 62, 9418-9437.	6.4	25
31	Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1669-1673.	2.2	24
32	Discovery of novel Jak2â€“Stat pathway inhibitors with extended residence time on target. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3105-3110.	2.2	20
33	In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2958-2961.	2.2	14
34	Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1336-1341.	2.2	13
35	The structure of human GCN2 reveals a parallel, back-to-back kinase dimer with a plastic DFG activation loop motif. Biochemical Journal, 2020, 477, 275-284.	3.7	13
36	Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement. Journal of Medicinal Chemistry, 2021, 64, 15189-15213.	6.4	12

#	Article	IF	Citations
37	SitePrint:â€‰Three-Dimensional Pharmacophore Descriptors Derived from Protein Binding Sites for Family Based Active Site Analysis, Classification, and Drug Design. Journal of Chemical Information and Computer Sciences, 2004, 44, 2190-2198.	2.8	11
38	Design of a gene family screening library targeting G-protein coupled receptors. Journal of Molecular Graphics and Modelling, 2004, 23, 15-21.	2.4	9
39	Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4775-4780.	2.2	6
40	Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods. ACS Chemical Biology, 2022, 17, 54-67.	3.4	6
41	AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia. Blood, 2011, 118, 1540-1540.	1.4	4
42	Script-based automation of analytical instrument software tasks. SLAS Technology, 2021, , .	1.9	0